New: our own Hairmetry line. Every ingredient explained

Encyclopedia · drug with hair side effects

Breast cancer endocrine therapy (tamoxifen, aromatase inhibitors)

Anti-estrogen pills taken for years after breast cancer can cause female pattern-type thinning, and in one uncontrolled series topical minoxidil helped 80% of those assessed.

Prescription medicine, used off-label for hair Cost $ Safety: moderate

hair lossthinning

What it is

Prescription drugs that block estrogen's action (tamoxifen) or its production (aromatase inhibitors) to prevent breast cancer recurrence, usually taken for 5-10 years.

How it works

Estrogen helps keep follicles in the growth phase and balances androgens. Lowering or blocking it can reveal pattern-type thinning, which matched the pattern authors saw: similar to androgenetic-type. Freites-Martinez 2018

What the studies show

  • In 112 women seen at a cancer-centre dermatology service, 67% of cases were attributed to aromatase inhibitors and 33% to tamoxifen. Of those graded, 92% had grade 1 (mild) severity, and quality of life was affected mainly emotionally. Freites-Martinez 2018
  • Of 46 assessed on topical minoxidil, 37 (80%) improved moderately or significantly by single-blinded photo review, with no control group. Freites-Martinez 2018
  • Only patients referred with alopecia were included, so this study cannot give an incidence.

How it's used in studies

Topical minoxidil as per the clinic; doses were not described in the abstract.

Side effects and safety

Do not stop cancer endocrine therapy because of thinning without the oncology team, since the drug may protect survival. For topical minoxidil see minoxidil.

Bottom line

Real, usually mild and possibly treatable, based on one uncontrolled series. It supports counselling before therapy. Discuss with a doctor.

Fun facts

  • A drug that lowers estrogen produces pattern-type thinning, a clue that hair is sensitive to the estrogen and androgen balance.

Studies 1

Freites-Martinez A et al. Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol. 2018

Design
cohort
People
112
Who
women with breast cancer referred with alopecia on endocrine therapy

Result: 67% on aromatase inhibitors, 33% on tamoxifen; 92% of graded patients had grade 1; topical minoxidil improved 37 of 46 (80%), uncontrolled.

Read the study ↗